Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,098 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy Volunteers
Interventions: SXC-2023, Placebo; Drug
Lead sponsor: Promentis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Parkinson's Disease
Interventions: XC130-A10H, Placebo; Drug
Lead sponsor: Xoc Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Risdiplam, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions: MLN3126, MLN3126 Matched Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Vision, Entoptic
Interventions: 12 mg Lutein + Zeaxanthin, Visually identical placebo; Dietary Supplement
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Onychomycosis
Interventions: Albaconozole, Placebo; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Schizophrenia
Interventions: AVL-3288, Placebo; Device · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteer
Interventions: MT1013; Drug
Lead sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Thrombosis
Interventions: E-WE Thrombin- Dose 1, E-WE Thrombin- Dose 2, E-WE Thrombin- Dose 3, E-WE Thrombin- Dose 4, Placebo; Drug · Other
Lead sponsor: Aronora, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Adult Subjects
Interventions: GMI-1271, Placebo; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 19 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Muscular Dystrophies
Interventions: GSK3439171A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriasis
Interventions: CNTO 1959; Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Miramar, Florida + 5 more

Conditions: Healthy
Interventions: tucatinib, placebo, moxifloxacin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: GSK1265744 30mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, 0.5 mgTestosterone + 10 mg Buspirone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more

Conditions: Wounds
Interventions: Placebo gel, GLYC-101 gel (1.0 %); Drug
Lead sponsor: TR Therapeutics; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Healthy
Interventions: QAX576; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Adults
Interventions: BMS-986089, Placebo matching with BMS-986089; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteer
Interventions: Phenelzine, Tyramine, Phenelzine placebo, ozanimod placebo, ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pneumococcal Vaccines
Interventions: 31-valent pneumococcal conjugate vaccine, PCV20; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

Macular Pigment and Glare Disability

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

MT1013 Clinical TRIAL In Healthy Subject

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

ONO-7746 Study in Healthy Adult Subject